CXC Chemokines and HIV Pathogenesis

CXC 趋化因子和 HIV 发病机制

• 批准号: 6946547
• 负责人: David Michael Markovitz
• 金额: $ 18.17万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-04-15 至 2009-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6946547
• 关键词: chemokine; chemokine receptor; clinical research; human immunodeficiency virus 1; human subject; interleukin 8; macrophage; molecular pathology; nuclear factor kappa beta; pathologic process; protein kinase C; tissue /cell culture; virus infection mechanism; virus replication

DESCRIPTION (provided by applicant): We have recently shown that when monocyte-derived macrophages (MDM) are exposed to HIV-1, they produce large amounts of two C-X-C chemokines: Interleukin 8 (IL-8) and Growth-Regulated Oncogene alpha (GRO-alpha). This stimulation appears to be mediated by a pathway involving a tyrosine kinase, PKC-zeta, and perhaps NF-kappaB. IL-8 and GRO-alpha then, in turn, feed back and stimulate HIV-1 replication in both MDM and lymphocytes, likely by increasing viral entry. By blocking these chemokines or their receptors, CXCR1and/or CXCR2, we can inhibit HTV-1 replication. Companies have already developed agents that block the function of the above chemokines in order to treat inflammatory diseases, and we have demonstrated that a small molecule inhibitor of CXCR2 is able to inhibit HIV-1 replication. We now propose to examine the magnitude to which diverse clinical isolates of HIV stimulate the production of GRO-alpha and EL-8. The effect of IL-8 and GRO-alpha on the replication of a range of HIV isolates will also be assessed. These experiments will clarify how broadly applicable, and hence clinically important, these autocrine/paracrine loops involving chemokine, receptor, and HIV are. We will further test the hypothesis that HIV stimulates PKC-zeta and hence NF-kappaB, leading to increased transcription and production of IL-8 and GRO-alpha, which in turn stimulate HIV replication by augmenting viral entry. Thus, the proposed studies aim to further validate GRO-alpha and EL-8 and their receptors as targets for antiretroviral therapy. A mechanistic understanding of the interactions between HIV and these C-X-C chemokines could lead to the development of new approaches to the treatment of patients infected with HIV.

描述（由申请人提供）：我们最近表明，当单核细胞衍生的巨噬细胞（MDM）暴露于HIV-1时，它们产生大量的两种C-X-C趋化因子：白细胞介素8（IL-8）和生长调节癌基因α（GRO-α）。这种刺激似乎是由涉及酪氨酸激酶、PKC-zeta和可能的NF-κ B的途径介导的。然后，IL-8和GRO-α反过来反馈并刺激HIV-1在MDM和淋巴细胞中的复制，可能是通过增加病毒进入。通过阻断这些趋化因子或其受体CXCR 1和/或CXCR 2，我们可以抑制HIV-1的复制。公司已经开发出阻断上述趋化因子功能的药物，以治疗炎症性疾病，我们已经证明CXCR 2的小分子抑制剂能够抑制HIV-1复制。我们现在建议检查不同的HIV临床分离株刺激GRO-α和EL-8产生的程度。还将评估IL-8和GRO-α对一系列HIV分离株复制的影响。这些实验将阐明这些涉及趋化因子、受体和HIV的自分泌/旁分泌循环的广泛适用性和临床重要性。我们将进一步检验HIV刺激PKC-zeta，从而刺激NF-κ B，导致IL-8和GRO-α的转录和产生增加，进而通过增强病毒进入刺激HIV复制的假设。因此，拟议的 研究旨在进一步验证GRO-α和EL-8及其受体作为抗逆转录病毒治疗的靶点。对HIV和这些C-X-C趋化因子之间相互作用的机制理解可能会导致开发治疗HIV感染患者的新方法。